Research Tracker›Biomarker Atlas›PACVS›Spike (LC-MS/MS quantification)

Spike (LC-MS/MS quantification) in PACVS

In PACVS (PACVS, PCVS), the direction of change for Spike (LC-MS/MS quantification), also described as Immunocapture + mass spectrometry, is inconsistent across studies that used healthy controls as the reference group. The cited literature links this alteration to quantitative vaccine-encoded spike detection. The evidence summarised here comes from Sutton et al. 2023 and reflects averages across cohorts rather than any single patient's result.

↕ InconsistentProteomic

Summary

Direction in PACVS↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction
CategoryProteomic
Also described asImmunocapture + mass spectrometry
Compared againstHC (healthy controls)
Associated symptomsQuantitative vaccine-encoded spike detection
Test typeBlood test (serum / plasma / whole blood)
SourceSutton et al. 2023 — doi:10.1016/j.vaccine.2023.04.044
Condition atlasPACVS Biomarker Atlas

Related Proteomic markers in PACVS

Full list: PACVS Biomarker Atlas.

Frequently asked questions

Is Spike (LC-MS/MS quantification) high or low in PACVS?

Mixed. Some studies report higher and others lower Spike (LC-MS/MS quantification) in PACVS compared with healthy controls, so no single direction is established. Source: Sutton et al. 2023.

What symptoms is Spike (LC-MS/MS quantification) associated with in PACVS?

The cited literature associates this marker with Quantitative vaccine-encoded spike detection. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Spike (LC-MS/MS quantification)?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Spike (LC-MS/MS quantification) result diagnostic of PACVS?

No. No single biomarker is diagnostic of PACVS. Spike (LC-MS/MS quantification) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Spike (LC-MS/MS quantification) in PACVS: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/pacvs/spike-lc-ms-ms-quantification.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-30 · Page generated from pacvs.json · Browse: PACVS atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.